SelSym Biotech’s Post

The technology behind SymClot was recently featured by NHLBI, with a focus on work funded by an STTR. This work has the potential to completely change how we manage traumatic bleeding in the field, and in hospital/clinic-based emergency and surgical settings. Not only does the product act as an "artificial platelet", thereby providing an avenue to replacing hard-to-store and difficult-to-transport platelet-based products, it also has the potential to be the first line of treatment for bleeding even in cases where platelets wouldn't be normally used. We are focused on transforming the standards of care in bleeding management and wound healing, and SymClot is poised to become the the lead product in that mission. https://lnkd.in/g3fSFcCC

A potential game-changer for emergency medicine: synthetic platelets

A potential game-changer for emergency medicine: synthetic platelets

nhlbi.nih.gov

To view or add a comment, sign in

Explore topics